Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Been here since 2008
In ARYC since 2014
Got most of my shares @ .0075 in 2017
I know what crap is...and isn’t
Been through it all
Love the green paint!
Yeah, how ‘bout them CHIEFS!
Mahomes needs to be running the show here....go ARYC!
Nice find...
“This test is performed in a CLIA lab, which operates in a Class 100 Microarray clean room.
FOR A CLINICAL LABORATORY TO BE “CLIA” CERTIFIED, THE LAB MUST BE FDA CLEARED TO DO HIGH COMPLEXITY TESTING. THEREFORE, THE LABORATORY MUST MEET A VERY STRINGENT GRADE OF ACCURACY *AT OR ABOVE 95% SPECIFICITY AND 95% SELECTIVITY.
*Meaning the margin of error for a false positive or false negative cannot exceed 5%.
This technology underwent FDA clearance initially in 2009 and since that time, has continued to expand its testing capability, now up to 180 food-related and environmental allergen associated IgE subsets, including latex and penicillin.
The test measures IgE antibody levels in blood using the same allergens from manufacturing facilities with FDA inspected skin-testing extracts and FDA approved immunotherapies.
The test is highly miniaturized and multiplexed, which enables all allergens, total IgE, and controls to be run simultaneously, in triplicate, with only a finger stick collection of blood. A simultaneous miniaturized reaction, with a high level of technical replication, dramatically reduces testing variability and false positive and negative results. Miniaturization combined with fluorescent detection makes the test very sensitive and quantitative for an accurate ranking of the IgE antibody levels to each allergen on the microarray.”
https://www.lenusallergysolutiontesting.com/refrences
I imagine you’ve already presented this info to the board but...
Looks like OMIT has been in Japan since 2016 and Australia since 2017.
Not to mention contact and possible submission to the FDA...
All of this would include our allergy finger stick test through Allovate.
About Allovate Therapeutics
Allovate Therapeutics is a New York-based biotechnology company founded in 2012 with the mission to improve allergy treatment for all patients. Allovate’s aim is to provide safe, effective, and convenient new options for allergy sufferers that deliver demonstrable improvements to therapeutic adherence and clinical outcomes over existing allergy treatment protocols. Allovate’s lead product, Allerdent®, is designed to deliver proteins, such as immunotherapeutic agents, to the immune system while the user brushes their teeth. Allovate’s licensee, Intrommune Therapeutics, is exploring allergy immunotherapy for life-threatening food allergies.
Intrommune Therapeutics
2013 - 2019: Multiple clinical publications demonstrating sublingual drops delivered under the tongue, also known as SLIT, can be a safe and effective treatment for peanut allergy. SLIT is similar to OMIT in that it brings food allergens into regular, brief contact with oral tissues. These successful SLIT studies therefore provide compelling evidence that OMIT can treat peanut allergy patients.
December 2015: Intrommune Therapeutics established as a company.
December 2015: Intrommune Therapeutics licenses global rights to develop food allergy OMIT from Allovate Therapeutics.
January - May 2016 - Intrommune assembles scientific advisory board of accomplished academic research thought-leaders in clinical immunology, pediatrics, and food allergy.
March 2016 - Initial patent for OMIT for food allergies issued in the United States.
April 2016 - Publication of 12 month pilot study demonstrating OMIT safety and efficacy to be comparable to SLIT in reducing airborne allergy symptoms.
December 2016 - First patent for OMIT for food allergies issued in Japan.
January 2017 - Patent for OMIT for food allergies issued in Australia.
November 2017 - Second patent for OMIT for food allergies issued in Japan.
December 2017 - License agreement is amended.
2016 to 2018 - Pre-clinical and clinical trial protocols developed in conjunction with food allergy experts, patients and clinical trial experts.
May 2018 - Submitted Pre-IND Meeting Request to the U.S. FDA
May 2018 - Eighth Annual BioNJ BioPartnering Conference
July 2018 - 72nd National Angel-VC Summit & Growth Capital Forum
July 2018 - Pre-IND Meeting With the U.S. FDA
March 2019 - European Patent Office (EPO) granted patent covering OMIT for Food Allergy
May 2019 - Intrommune Therapeutics Receives Best Private Company Presentation Award at BioNJ’s 9th Annual BioPartnering Conference
June 2019 - Biotechnology Entrepreneurship Boot Camp
June 2019 - PCCI Bridgewater Meeting
August 2019 - US Patent and Trademark Office (USPTO) issued a Notice of Allowance for its patent application titled, “Toothpaste for Delivery of Allergens to the Oral Mucosa.”
September 2019 - Asthma & Allergy Network Letter of Support provided to Intrommune Therapeutics
My pleasure. All sorts of tid-bits out there.
Japan and Australia as well.
I wonder how long that’s been going on? And how much they’ve saturated the market...
“These claims provide patent protection of the novel oral mucosal immunotherapy (OMIT) platform. Patents protecting OMIT have previously issued in the United States, Japan, and Australia.
Allovate retains the global rights to develop products based on the OMIT platform for the treatment of respiratory allergies. Allovate has licensed the rights to develop the OMIT platform for the treatment of food allergies to Intrommune Therapeutics, which is initially focused on an FDA-approved treatment for peanut allergy. Food allergy is a potentially life-threatening condition for which there is currently no treatment available.
Dr. Erick Berglund, Co-Founder and CEO of Allovate Therapeutics, said, “The grant of this key patent further validates the novelty of the OMIT platform and enables us to accelerate the development of new options for allergy sufferers. The claims of the new patent significantly enhance the commercial viability of Allovate Therapeutics.”
This one Development Agreement with the USDA may end but that still leaves them their exclusive license to commercialize the technology.
“The ongoing Cooperative Research and Development Agreement (CRADA) between Arrayit Corporation (ARYC) and the United States Department of Agriculture (USDA), "Rapid and Cost Effective Detection Technologies for Noroviruses and other Foodborne Pathogens," entitles Arrayit to an exclusive license to commercialize the technology.
Much of the food consumed in the United States, including 50% of the produce the US consumes during the winter months, is grown outside of the country. Arrayit and the USDA are expanding their food safety testing patent filings worldwide to include key food producing nations including Brazil, Canada, China, the European Union, Mexico and Peru.
Arrayit and the USDA Agricultural Research Service (ARS) have developed a rapid, portable, cost-effective and high-throughput detection system for the surveillance of multiple bacterial and viral foodborne pathogens including Campylobacter, E. coli, hepatitis, Listeria, norovirus and Salmonella. Expanding the USDA's patent protection will allow commercial licensing opportunities for Arrayit in jurisdictions worldwide.”
It’s going to be integral and affect EVERY FACET of the revolutionary Wellness directive!
It will be the new standard of perfecting and maintaining your health and healthcare.
PAS/OAS MedRx...is going to be HUGE!!!
Publication #342006
Research Project: Molecular Identification and Characterization of Bacterial and Viral Pathogens Associated with Foods
Location: Produce Safety and Microbiology Research
Title: Sensitive genotyping of foodborne-associated human noroviruses and hepatitis A virus using an array-based platform
Author
Quiñones, Beatriz
Lee, Bertram
Martinsky, Todd - Arrayit Corporation
Yambao, Jaszemyn
Haje, Paul - Arrayit Corporation
Schena, Mark - Arrayit Corporation
Submitted to: Sensors
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 9/18/2017
Publication Date: 9/20/2017
Citation: Quinones, B., Lee, B.G., Martinsky, T.J., Yambao, J.C., Haje, P.K., Schena, M. 2017. Sensitive genotyping of foodborne-associated human noroviruses and hepatitis A virus using an array-based platform. Sensors. 17(9):2157. https://doi.org/10.3390/s17092157.
DOI: https://doi.org/10.3390/s17092157
https://www.ars.usda.gov/research/publications/publication/?seqNo115=342006
Word games...oh my...poor, pitiful us...the sky is falling...
Bad stock, Arrayit...bad.
I bet there’s a few of theses companies using Arrayit products to isolate the virus.
Investors rush into biotechs working on coronavirus vaccine
https://www.cnbc.com/2020/02/01/heres-your-guide-to-biotech-companies-working-on-coronavirus.html
The SEC has no issue with it within their guidelines, yes.
One take away from all these financial arrangements.
PCSO share price has got to go up to support or sustain any of it.
Same as 10 years ago.
It makes sense only if you're diving down a rabbit hole while you read it.
How far down do you want to go?
Wow, I have almost 1% of the float...
True. The new activity seems to be within the realm of possibility.
They actually believe they have a product and a business plan that is viable. Or they don't and are just trying to create attention.
On its face, First Group's website shows a lot of transparency. I just haven't reviewed it all yet to decide for myself.
Going along for the ride for now.
Climate must be right for a boutique financial institution I guess...or a pump.
Are they really insinuating that my shares are valued over $400 apiece?
“Example: Between 2006 – 2009, the public price per share ranged as low as $.01. From 2007 – 2009 the private market price averaged $21. From 2009 to the present, the negotiated private market price is over $400 per share.
Therefore, re-packaging the PCSO stock into BCLOC (which consists of a pool of equity, treasury, annuity and accreted interest) affirms PSCO stock has substantially increased in value.”
Yeah, I kinda recognize the smoke and mirrors.
Consider me a badly burnt skeptic.
Still here, still hopin'.
Arrayit payin’ the bills...must have loads of cash comin' in!!
PROGRESS IN CLIENTS BUSINESS ACTIVITES
In reliance upon the pre-audit book value as a threshold price, clients are expected to sell stocks on a stand-alone basis. If the stocks are sold in concurrent with the customer issuing bonds through our guarantee company - First Life Financial Corporation, the customer is expected to be able to execute her business plans over the next three or more years.
Thus, Relm Real Estate Holdings (RREH) has identified a management team to design, build or construct luxury hotel complexes around the globe that is expected to consist of luxury hotels on a scale equal to or greater than the Four Seasons or Ritz Carton which would be connected to luxury condos priced in the Four Seasons market.
Restoration is looking to developing upscale housing units to satisfy the market of people in the income level of approximately $300 thousand and up.
Also, the company (PCSO) intends to issue $5 billion or more bonds through First Life Financial Corporation to develop and resource the U.S. Treasury Fund to enhance BCLOC corporate clients with additional liquidity to develop their respective businesses. During the bond capital raise, there is a high probability that management would setup a bond sinking fund to service or help make interest payments on the Notes.
While the accounts receivable balance on the balance sheet continues to increase, our commitment to responsible management enables us to implement the necessary strategy to pursue the reduction of the receivables by negotiating with clients (based on agreement) to pay by issuing securities. When payment is received in securities, we would place the securities in an escrow account within a FINRA broker-dealer firm, and make them available for sale during a twelve months period.
However, during the construction phase, quantity of shares that is likely to be sold may be less until the properties are fully developed. If the securities are not sold within the twelve-month period, the process will continue until the securities are converted to cash to pay-off the outstanding interests in full.
“Um...” Its called due diligence as to Arrayit’s current status. The FDA acknowledges Arrayit as an on-going entity and could still be doing business with.
Assessing the current landscape per se...
DUNS NUMBER: 962379470
BUSINESS NAME: Arrayit Corporation
COUNTRY NAME: USA
TICKER SYMBOL: ARYC
EXCHANGE NAME: OTHER OTC Market
-
-
Page Last Updated: 01/03/2020
This is why...
MikeCr
Re: None 0
Post # of 169585
Next court date for Iconic case. 1/10/20
1/10/20
Motion Hearing (Civil) - Motion for Preliminary Injunction filed by ARYC to prevent Iconic from
Quote:
(1) from transferring, liquidating, converting, encumbering, pledging, loaning, selling,
concealing, dissipating, disbursing, assigning, spending, withdrawing, gifting, conveying,
hypothecating, using as collateral, or otherwise disposing or acquiring any of Arrayit’s common
stock.
This motion is made pursuant to the court’s November 13, 2018 Order After Hearing and
the provisions of Code of Civil Procedure section 527 on the ground that Defendant Iconic has
made repeated efforts to remove the restrictive legend on shares that are in dispute in this
litigation and that the disposal of said shares would cause irreparable harm to Arrayit.
...emphasis added...
Repost from:
MikeCr
Re: None 0
Post # of 169585
Next court date for Iconic case. 1/10/20
1/10/20
Motion Hearing (Civil) - Motion for Preliminary Injunction filed by ARYC to prevent Iconic from
Quote:
(1) from transferring, liquidating, converting, encumbering, pledging, loaning, selling,
concealing, dissipating, disbursing, assigning, spending, withdrawing, gifting, conveying,
hypothecating, using as collateral, or otherwise disposing or acquiring any of Arrayit’s common
stock.
This motion is made pursuant to the court’s November 13, 2018 Order After Hearing and
the provisions of Code of Civil Procedure section 527 on the ground that Defendant Iconic has
made repeated efforts to remove the restrictive legend on shares that are in dispute in this
litigation and that the disposal of said shares would cause irreparable harm to Arrayit.
...emphasis added...
So there we have it...
Here’s their (our) sample report:
https://18a0e78b-a0e1-4542-948f-b92d6aa87696.filesusr.com/ugd/2b19c7_a8694c53c9384eb586e92bb73d9257af.pdf
At the bottom of each page:
©2017 PatientDataSolutions.com Form 102.01
https://www.patientdatasolutions.com/
I like the last bullet point...
“Assisted $220M market cap 2019”
It’s the most financial information we have had in four years.
Nielsen sold at .04 and now he's buying at .02!
A great scientist, but could sure use some help running a business...
Mark Alden Schena (born May 21, 1963) is an American biochemist and president of a public life sciences health care company.[clarification needed]
During his studies at Berkeley, Schena showed that changes in citrate synthase expression cause changes in flux through the citric acid cycle.[1] This work showed the importance of rate limiting steps in enzymatic pathways. As a graduate student at UCSF, Schena discovered the evolutionary conservation of cellular mechanisms across eukaryotic evolution by demonstrating the conservation of mammalian glucocorticoid receptor function in the yeast Saccharomyces cerevisiae.[2] At Stanford, Schena pioneered a new field of science (microarray technology) as the first author on the Stanford team publication in the journal Science demonstrating that complementary DNA molecules immobilized on glass could be used to measure gene expression in the flowering plant Arabidopsis thaliana.[3] The modern microarray industry and solid-phase DNA sequencing industry have drawn heavily from the 1995 Science paper. More than 42,000 peer-reviewed microarray publications have appeared in the scientific literature since 1995.[4]
Schena has written four books on microarrays,[5][6][7][8] including the first textbook on the subject,[9] and has been featured by journalists in interviews covered by the print media, radio and television.[10] Schena has pioneered an extensive line of microarray products and services at Arrayit[clarification needed]. Schena is the inventor of Variation Identification Platform (VIP) technology, which is capable of genotyping up to 80,000 patients in a single microarray test.[11] Schena has taken an active role in healthcare reform in the United States by promoting the importance of technical innovation as a means of improving the quality and accessibility of healthcare and controlling its cost.[12] Schena is considered the foremost authority on microarray technology, referred to as the "Father of Microarray Technology".[13]
In 2001, Schena was featured on the Nova television documentary "Cracking the Code of Life", a two-hour special hosted by ABC News Nightline correspondent Robert Krulwich.[14] Schena first introduced microarrays as pre-symptomatic diagnostic tools on the 2001 Nova program. Schena holds the first and second positions on "The Microarray Family Tree", a historiograph of 13 influential papers published in the microarray field, written by Eugene Garfield.[15] The Scientist also credited Schena with creating the first array.[16] Schena was proclaimed the "Father of Microarrays" in an article written by Lloyd Dunlap, contributing editor of Drug Discovery News, in an account of Schena's pioneering work to decipher Parkinson's disease.[17] Schena and Rene Schena reside in Los Altos, California.[citation needed]
https://en.m.wikipedia.org/wiki/Mark_Schena
The way she talks, sounds like the new initial price listing standards are currently active.
Great, new possibilities for a Arrayit!
Arrayit Corporation invited to appear on leading half hour business talk show Spotlight Television airing on Fox Business Network and featuring inspiring leaders and innovative healthcare services to a national television audience of 85 million subscribers spotlighttelevision.com
I wonder if they’ll appear and what they’ll say...?
Arrayit Corporation invited to appear on leading half hour business talk show Spotlight Television airing on Fox Business Network and featuring inspiring leaders and innovative healthcare services to a national television audience of 85 million subscribers https://t.co/GanzSfF9Tb pic.twitter.com/vRH6DxAGhz
— Arrayit Corporation (@arrayit) August 5, 2019
I suspect your hopes are well-founded. I know I wouldn't put anything on the production line unless I knew that it was sold and out the door in short order. Or a contract on a certain amount of production...